Platelet-rich Plasma(PRP) Injection in ED

NCT ID: NCT05241964

Last Updated: 2022-02-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-22

Study Completion Date

2022-11-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RPR contains rich-in growth factors and has the properties of helping tissue regeneration and nerve repair. In theory, it is possibility of curing ED.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There are many reasons of erectile dysfunction(ED). If left untreated, there is a major impact on relationships, self-esteem, and overall health. RPR contains rich-in growth factors and has the properties of helping tissue regeneration and nerve repair. Its mechanism is to promote the regeneration of blood vessels in the cavernous body of the penis, increase blood circulation, and then help erection, increase penile stiffness and improve the phenomenon of premature ejaculation. The main purpose of this study is to study the safety and effectiveness of PRP injection for the treatment of ED.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erectile Dysfunction PRP

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRP

PRP injection

Group Type EXPERIMENTAL

PRP

Intervention Type BIOLOGICAL

4\~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRP

4\~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* Between 20 and 70 years old
* Sexual dysfunction exists for at least 6 months
* IIEF-5 score 8-2
* Sign an informed consent form

Exclusion Criteria

* Ever radical prostatectomy or extensive pelvic surgery
* Radiation therapy to the pelvic area within 12 months before recruiting
* Cancer
* Nervous system diseases that affect erectile function
* Have any blood disease
* History of coronary artery disease
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

I-Ni Chiang, MD

Role: PRINCIPAL_INVESTIGATOR

Taipei Veteran General hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Taiwan University Hospital

Taipei, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

I-Ni Chiang, MD

Role: CONTACT

+886919077219

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

I-NI CHIANG, MD

Role: primary

Role: backup

+886919077219

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202008061RIPC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PRP for Treatment of Peyronie's Disease
NCT04512287 COMPLETED PHASE2
Erectile Dysfunction Treatment Using Stem Cells
NCT06550752 NOT_YET_RECRUITING PHASE1/PHASE2